Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 106 entries
Sorted by: Best Match Show Resources per page
Correction to: Clinical Pharmacokinetic Characteristics of Cebranopadol, a Novel First-in-Class Analgesic.

Clinical pharmacokinetics

Kleideiter E, Piana C, Wang S, Nemeth R, Gautrois M.
PMID: 29949019
Clin Pharmacokinet. 2018 Aug;57(8):1057-1058. doi: 10.1007/s40262-018-0686-x.

For each simulation, PK profiles from 1000 subjects were simulated based on a titration scheme.

Cite
Kleideiter E, Piana C, Wang S, et al. Correction to: Clinical Pharmacokinetic Characteristics of Cebranopadol, a Novel First-in-Class Analgesic. Clin Pharmacokinet. 2018;57(8):1057-1058doi: 10.1007/s40262-018-0686-x.
Kleideiter, E., Piana, C., Wang, S., Nemeth, R., & Gautrois, M. (2018). Correction to: Clinical Pharmacokinetic Characteristics of Cebranopadol, a Novel First-in-Class Analgesic. Clinical pharmacokinetics, 57(8), 1057-1058. https://doi.org/10.1007/s40262-018-0686-x
Kleideiter, Elke, et al. "Correction to: Clinical Pharmacokinetic Characteristics of Cebranopadol, a Novel First-in-Class Analgesic." Clinical pharmacokinetics vol. 57,8 (2018): 1057-1058. doi: https://doi.org/10.1007/s40262-018-0686-x
Kleideiter E, Piana C, Wang S, Nemeth R, Gautrois M. Correction to: Clinical Pharmacokinetic Characteristics of Cebranopadol, a Novel First-in-Class Analgesic. Clin Pharmacokinet. 2018 Aug;57(8):1057-1058. doi: 10.1007/s40262-018-0686-x. PMID: 29949019; PMCID: PMC6028882.
Copy Download .nbib Format: NLM
Metformin Transport Rates Between Plasma and Red Blood Cells in Humans.

Clinical pharmacokinetics

Kurlovics J, Zake DM, Zaharenko L, Berzins K, Klovins J, Stalidzans E.
PMID: 34309806
Clin Pharmacokinet. 2021 Jul 26; doi: 10.1007/s40262-021-01058-2. Epub 2021 Jul 26.

BACKGROUND: Metformin has been used for the treatment of type 2 diabetes for over 60 years; however, its mechanism of pharmacological action is not fully clear. Different hypotheses exist regarding metformin distribution and redistribution mechanisms between plasma and erythrocytes/red...

Cite
Kurlovics J, Zake DM, Zaharenko L, et al. Metformin Transport Rates Between Plasma and Red Blood Cells in Humans. Clin Pharmacokinet. 2021;doi: 10.1007/s40262-021-01058-2.
Kurlovics, J., Zake, D. M., Zaharenko, L., Berzins, K., Klovins, J., & Stalidzans, E. (2021). Metformin Transport Rates Between Plasma and Red Blood Cells in Humans. Clinical pharmacokinetics, . https://doi.org/10.1007/s40262-021-01058-2
Kurlovics, Janis, et al. "Metformin Transport Rates Between Plasma and Red Blood Cells in Humans." Clinical pharmacokinetics vol. (2021). doi: https://doi.org/10.1007/s40262-021-01058-2
Kurlovics J, Zake DM, Zaharenko L, Berzins K, Klovins J, Stalidzans E. Metformin Transport Rates Between Plasma and Red Blood Cells in Humans. Clin Pharmacokinet. 2021 Jul 26; doi: 10.1007/s40262-021-01058-2. Epub 2021 Jul 26. PMID: 34309806.
Copy Download .nbib Format: NLM
Therapeutic Drug Monitoring of Endoxifen for Tamoxifen Precision Dosing: Feasible in Patients with Hormone-Sensitive Breast Cancer.

Clinical pharmacokinetics

Braal CL, Jager A, Hoop EO, Westenberg JD, Lommen KMWT, de Bruijn P, Vastbinder MB, van Rossum-Schornagel QC, Thijs-Visser MF, van Alphen RJ, Struik LEM, Zuetenhorst HJM, Mathijssen RHJ, Koolen SLW.
PMID: 34786650
Clin Pharmacokinet. 2021 Nov 17; doi: 10.1007/s40262-021-01077-z. Epub 2021 Nov 17.

BACKGROUND: Endoxifen is the most important active metabolite of tamoxifen. Several retrospective studies have suggested a minimal or threshold endoxifen systemic concentration of 14-16 nM is required for a lower recurrence rate. The aim of this study was to...

Cite
Braal CL, Jager A, Hoop EO, et al. Therapeutic Drug Monitoring of Endoxifen for Tamoxifen Precision Dosing: Feasible in Patients with Hormone-Sensitive Breast Cancer. Clin Pharmacokinet. 2021;doi: 10.1007/s40262-021-01077-z.
Braal, C. L., Jager, A., Hoop, E. O., Westenberg, J. D., Lommen, K. M. W. T., de Bruijn, P., Vastbinder, M. B., van Rossum-Schornagel, Q. C., Thijs-Visser, M. F., van Alphen, R. J., Struik, L. E. M., Zuetenhorst, H. J. M., Mathijssen, R. H. J., & Koolen, S. L. W. (2021). Therapeutic Drug Monitoring of Endoxifen for Tamoxifen Precision Dosing: Feasible in Patients with Hormone-Sensitive Breast Cancer. Clinical pharmacokinetics, . https://doi.org/10.1007/s40262-021-01077-z
Braal, C Louwrens, et al. "Therapeutic Drug Monitoring of Endoxifen for Tamoxifen Precision Dosing: Feasible in Patients with Hormone-Sensitive Breast Cancer." Clinical pharmacokinetics vol. (2021). doi: https://doi.org/10.1007/s40262-021-01077-z
Braal CL, Jager A, Hoop EO, Westenberg JD, Lommen KMWT, de Bruijn P, Vastbinder MB, van Rossum-Schornagel QC, Thijs-Visser MF, van Alphen RJ, Struik LEM, Zuetenhorst HJM, Mathijssen RHJ, Koolen SLW. Therapeutic Drug Monitoring of Endoxifen for Tamoxifen Precision Dosing: Feasible in Patients with Hormone-Sensitive Breast Cancer. Clin Pharmacokinet. 2021 Nov 17; doi: 10.1007/s40262-021-01077-z. Epub 2021 Nov 17. PMID: 34786650.
Copy Download .nbib Format: NLM
Finerenone Dose-Exposure-Serum Potassium Response Analysis of FIDELIO-DKD Phase III: The Role of Dosing, Titration, and Inclusion Criteria.

Clinical pharmacokinetics

Goulooze SC, Snelder N, Seelmann A, Horvat-Broecker A, Brinker M, Joseph A, Garmann D, Lippert J, Eissing T.
PMID: 34786651
Clin Pharmacokinet. 2021 Nov 17; doi: 10.1007/s40262-021-01083-1. Epub 2021 Nov 17.

BACKGROUND: Finerenone is a nonsteroidal selective mineralocorticoid receptor antagonist (MRA) that demonstrated efficacy in delaying the progression of chronic kidney disease (CKD) and reducing cardiovascular events in patients with CKD and type 2 diabetes mellitus in FIDELIO-DKD, where 5734...

Cite
Goulooze SC, Snelder N, Seelmann A, et al. Finerenone Dose-Exposure-Serum Potassium Response Analysis of FIDELIO-DKD Phase III: The Role of Dosing, Titration, and Inclusion Criteria. Clin Pharmacokinet. 2021;doi: 10.1007/s40262-021-01083-1.
Goulooze, S. C., Snelder, N., Seelmann, A., Horvat-Broecker, A., Brinker, M., Joseph, A., Garmann, D., Lippert, J., & Eissing, T. (2021). Finerenone Dose-Exposure-Serum Potassium Response Analysis of FIDELIO-DKD Phase III: The Role of Dosing, Titration, and Inclusion Criteria. Clinical pharmacokinetics, . https://doi.org/10.1007/s40262-021-01083-1
Goulooze, Sebastiaan Camiel, et al. "Finerenone Dose-Exposure-Serum Potassium Response Analysis of FIDELIO-DKD Phase III: The Role of Dosing, Titration, and Inclusion Criteria." Clinical pharmacokinetics vol. (2021). doi: https://doi.org/10.1007/s40262-021-01083-1
Goulooze SC, Snelder N, Seelmann A, Horvat-Broecker A, Brinker M, Joseph A, Garmann D, Lippert J, Eissing T. Finerenone Dose-Exposure-Serum Potassium Response Analysis of FIDELIO-DKD Phase III: The Role of Dosing, Titration, and Inclusion Criteria. Clin Pharmacokinet. 2021 Nov 17; doi: 10.1007/s40262-021-01083-1. Epub 2021 Nov 17. PMID: 34786651.
Copy Download .nbib Format: NLM
Authors' Reply to De Sutter, De Waele, and Vermeulen: "Penetration of Antibacterial Agents into Pulmonary Epithelial Lining Fluid: An Update".

Clinical pharmacokinetics

Drwiega EN, Rodvold KA.
PMID: 34982408
Clin Pharmacokinet. 2022 Jan 04; doi: 10.1007/s40262-021-01101-2. Epub 2022 Jan 04.

No abstract available.

Cite
Drwiega EN, Rodvold KA. Authors' Reply to De Sutter, De Waele, and Vermeulen: "Penetration of Antibacterial Agents into Pulmonary Epithelial Lining Fluid: An Update". Clin Pharmacokinet. 2022;doi: 10.1007/s40262-021-01101-2.
Drwiega, E. N., & Rodvold, K. A. (2022). Authors' Reply to De Sutter, De Waele, and Vermeulen: "Penetration of Antibacterial Agents into Pulmonary Epithelial Lining Fluid: An Update". Clinical pharmacokinetics, . https://doi.org/10.1007/s40262-021-01101-2
Drwiega, Emily N, and Rodvold, Keith A. "Authors' Reply to De Sutter, De Waele, and Vermeulen: "Penetration of Antibacterial Agents into Pulmonary Epithelial Lining Fluid: An Update"." Clinical pharmacokinetics vol. (2022). doi: https://doi.org/10.1007/s40262-021-01101-2
Drwiega EN, Rodvold KA. Authors' Reply to De Sutter, De Waele, and Vermeulen: "Penetration of Antibacterial Agents into Pulmonary Epithelial Lining Fluid: An Update". Clin Pharmacokinet. 2022 Jan 04; doi: 10.1007/s40262-021-01101-2. Epub 2022 Jan 04. PMID: 34982408.
Copy Download .nbib Format: NLM
Perpetrator Characteristics of Azole Antifungal Drugs on Three Oral Factor Xa Inhibitors Administered as a Microdosed Cocktail.

Clinical pharmacokinetics

Rohr BS, Foerster KI, Blank A, Burhenne J, Mahmoudi M, Haefeli WE, Mikus G.
PMID: 34273071
Clin Pharmacokinet. 2021 Jul 17; doi: 10.1007/s40262-021-01051-9. Epub 2021 Jul 17.

BACKGROUND: Factor Xa inhibitors (FXaIs) are increasingly used without having sufficient drug-drug interaction data. Using a microdosed cocktail methodology could support filling the knowledge gap quickly.METHODS: In a randomised crossover trial, we investigated the drug-drug interactions between six oral...

Cite
Rohr BS, Foerster KI, Blank A, et al. Perpetrator Characteristics of Azole Antifungal Drugs on Three Oral Factor Xa Inhibitors Administered as a Microdosed Cocktail. Clin Pharmacokinet. 2021;doi: 10.1007/s40262-021-01051-9.
Rohr, B. S., Foerster, K. I., Blank, A., Burhenne, J., Mahmoudi, M., Haefeli, W. E., & Mikus, G. (2021). Perpetrator Characteristics of Azole Antifungal Drugs on Three Oral Factor Xa Inhibitors Administered as a Microdosed Cocktail. Clinical pharmacokinetics, . https://doi.org/10.1007/s40262-021-01051-9
Rohr, Brit Silja, et al. "Perpetrator Characteristics of Azole Antifungal Drugs on Three Oral Factor Xa Inhibitors Administered as a Microdosed Cocktail." Clinical pharmacokinetics vol. (2021). doi: https://doi.org/10.1007/s40262-021-01051-9
Rohr BS, Foerster KI, Blank A, Burhenne J, Mahmoudi M, Haefeli WE, Mikus G. Perpetrator Characteristics of Azole Antifungal Drugs on Three Oral Factor Xa Inhibitors Administered as a Microdosed Cocktail. Clin Pharmacokinet. 2021 Jul 17; doi: 10.1007/s40262-021-01051-9. Epub 2021 Jul 17. PMID: 34273071.
Copy Download .nbib Format: NLM
Clinical Pharmacokinetics and Pharmacodynamics of the Selective Progesterone Receptor Modulator Vilaprisan: A Comprehensive Overview.

Clinical pharmacokinetics

Schultze-Mosgau MH, Ploeger BA, Frei M, Höchel J, Rottmann A.
PMID: 34569009
Clin Pharmacokinet. 2021 Sep 27; doi: 10.1007/s40262-021-01073-3. Epub 2021 Sep 27.

Vilaprisan is a highly potent selective progesterone receptor modulator in development for the treatment of symptomatic uterine fibroids and endometriosis. Its pharmacokinetics are characterized by rapid absorption, almost complete bioavailability, and dose-proportional exposure. The intrinsic factors of age, bodyweight,...

Cite
Schultze-Mosgau MH, Ploeger BA, Frei M, et al. Clinical Pharmacokinetics and Pharmacodynamics of the Selective Progesterone Receptor Modulator Vilaprisan: A Comprehensive Overview. Clin Pharmacokinet. 2021;doi: 10.1007/s40262-021-01073-3.
Schultze-Mosgau, M. H., Ploeger, B. A., Frei, M., Höchel, J., & Rottmann, A. (2021). Clinical Pharmacokinetics and Pharmacodynamics of the Selective Progesterone Receptor Modulator Vilaprisan: A Comprehensive Overview. Clinical pharmacokinetics, . https://doi.org/10.1007/s40262-021-01073-3
Schultze-Mosgau, Marcus-Hillert, et al. "Clinical Pharmacokinetics and Pharmacodynamics of the Selective Progesterone Receptor Modulator Vilaprisan: A Comprehensive Overview." Clinical pharmacokinetics vol. (2021). doi: https://doi.org/10.1007/s40262-021-01073-3
Schultze-Mosgau MH, Ploeger BA, Frei M, Höchel J, Rottmann A. Clinical Pharmacokinetics and Pharmacodynamics of the Selective Progesterone Receptor Modulator Vilaprisan: A Comprehensive Overview. Clin Pharmacokinet. 2021 Sep 27; doi: 10.1007/s40262-021-01073-3. Epub 2021 Sep 27. PMID: 34569009.
Copy Download .nbib Format: NLM
Clinical Pharmacokinetics and Pharmacodynamics of Cefiderocol.

Clinical pharmacokinetics

Bilal M, El Tabei L, Büsker S, Krauss C, Fuhr U, Taubert M.
PMID: 34420182
Clin Pharmacokinet. 2021 Dec;60(12):1495-1508. doi: 10.1007/s40262-021-01063-5. Epub 2021 Aug 22.

Cefiderocol is a new broad-spectrum cephalosporin antibiotic with promising activity against various Gram-negative bacteria including carbapenem-resistant strains. A chlorocatechol group in the C-3 side chain provides cefiderocol with a siderophore activity, improving its stability against β-lactamases and facilitating the...

Cite
Bilal M, El Tabei L, Büsker S, et al. Clinical Pharmacokinetics and Pharmacodynamics of Cefiderocol. Clin Pharmacokinet. 2021;60(12):1495-1508doi: 10.1007/s40262-021-01063-5.
Bilal, M., El Tabei, L., Büsker, S., Krauss, C., Fuhr, U., & Taubert, M. (2021). Clinical Pharmacokinetics and Pharmacodynamics of Cefiderocol. Clinical pharmacokinetics, 60(12), 1495-1508. https://doi.org/10.1007/s40262-021-01063-5
Bilal, Muhammad, et al. "Clinical Pharmacokinetics and Pharmacodynamics of Cefiderocol." Clinical pharmacokinetics vol. 60,12 (2021): 1495-1508. doi: https://doi.org/10.1007/s40262-021-01063-5
Bilal M, El Tabei L, Büsker S, Krauss C, Fuhr U, Taubert M. Clinical Pharmacokinetics and Pharmacodynamics of Cefiderocol. Clin Pharmacokinet. 2021 Dec;60(12):1495-1508. doi: 10.1007/s40262-021-01063-5. Epub 2021 Aug 22. PMID: 34420182; PMCID: PMC8613110.
Copy Download .nbib Format: NLM
Correction to: Clinical Pharmacokinetics of Atypical Antipsychotics: An Update.

Clinical pharmacokinetics

Mauri MC, Paletta S, Di Pace C, Reggiori A, Cirnigliaro G, Valli I, Altamura AC.
PMID: 31214940
Clin Pharmacokinet. 2019 Sep;58(9):1219-1220. doi: 10.1007/s40262-019-00797-7.

The pharmacokinetics of CRP was tested in small short-term studies in both healthy volunteers and in subjects with schizophrenia, with similar results [242].

Cite
Mauri MC, Paletta S, Di Pace C, et al. Correction to: Clinical Pharmacokinetics of Atypical Antipsychotics: An Update. Clin Pharmacokinet. 2019;58(9):1219-1220doi: 10.1007/s40262-019-00797-7.
Mauri, M. C., Paletta, S., Di Pace, C., Reggiori, A., Cirnigliaro, G., Valli, I., & Altamura, A. C. (2019). Correction to: Clinical Pharmacokinetics of Atypical Antipsychotics: An Update. Clinical pharmacokinetics, 58(9), 1219-1220. https://doi.org/10.1007/s40262-019-00797-7
Mauri, Massimo Carlo, et al. "Correction to: Clinical Pharmacokinetics of Atypical Antipsychotics: An Update." Clinical pharmacokinetics vol. 58,9 (2019): 1219-1220. doi: https://doi.org/10.1007/s40262-019-00797-7
Mauri MC, Paletta S, Di Pace C, Reggiori A, Cirnigliaro G, Valli I, Altamura AC. Correction to: Clinical Pharmacokinetics of Atypical Antipsychotics: An Update. Clin Pharmacokinet. 2019 Sep;58(9):1219-1220. doi: 10.1007/s40262-019-00797-7. PMID: 31214940.
Copy Download .nbib Format: NLM
An Update on Population Pharmacokinetic Analyses of Vancomycin, Part II: In Pediatric Patients.

Clinical pharmacokinetics

Aljutayli A, El-Haffaf I, Marsot A, Nekka F.
PMID: 34671937
Clin Pharmacokinet. 2021 Oct 21; doi: 10.1007/s40262-021-01050-w. Epub 2021 Oct 21.

Vancomycin is widely used in pediatric patients, however, large inter- and intraindividual variability are observed in vancomycin pharmacokinetics, affecting proper therapeutic monitoring. This review aimed at providing a comprehensive synthesis of the population pharmacokinetic models of vancomycin in pediatric...

Cite
Aljutayli A, El-Haffaf I, Marsot A, et al. An Update on Population Pharmacokinetic Analyses of Vancomycin, Part II: In Pediatric Patients. Clin Pharmacokinet. 2021;doi: 10.1007/s40262-021-01050-w.
Aljutayli, A., El-Haffaf, I., Marsot, A., & Nekka, F. (2021). An Update on Population Pharmacokinetic Analyses of Vancomycin, Part II: In Pediatric Patients. Clinical pharmacokinetics, . https://doi.org/10.1007/s40262-021-01050-w
Aljutayli, Abdullah, et al. "An Update on Population Pharmacokinetic Analyses of Vancomycin, Part II: In Pediatric Patients." Clinical pharmacokinetics vol. (2021). doi: https://doi.org/10.1007/s40262-021-01050-w
Aljutayli A, El-Haffaf I, Marsot A, Nekka F. An Update on Population Pharmacokinetic Analyses of Vancomycin, Part II: In Pediatric Patients. Clin Pharmacokinet. 2021 Oct 21; doi: 10.1007/s40262-021-01050-w. Epub 2021 Oct 21. PMID: 34671937.
Copy Download .nbib Format: NLM
Pharmacokinetic/Pharmacodynamic Modelling of Allopurinol, its Active Metabolite Oxypurinol, and Biomarkers Hypoxanthine, Xanthine and Uric Acid in Hypoxic-Ischemic Encephalopathy Neonates.

Clinical pharmacokinetics

Chu WY, Annink KV, Nijstad AL, Maiwald CA, Schroth M, Bakkali LE, van Bel F, Benders MJNL, van Weissenbruch MM, Hagen A, Franz AR, Dorlo TPC, Allegaert K, Huitema ADR.
PMID: 34617261
Clin Pharmacokinet. 2021 Oct 07; doi: 10.1007/s40262-021-01068-0. Epub 2021 Oct 07.

BACKGROUND: Allopurinol, an xanthine oxidase (XO) inhibitor, is a promising intervention that may provide neuroprotection for neonates with hypoxic-ischemic encephalopathy (HIE). Currently, a double-blind, placebo-controlled study (ALBINO, NCT03162653) is investigating the neuroprotective effect of allopurinol in HIE neonates.OBJECTIVE: The...

Cite
Chu WY, Annink KV, Nijstad AL, et al. Pharmacokinetic/Pharmacodynamic Modelling of Allopurinol, its Active Metabolite Oxypurinol, and Biomarkers Hypoxanthine, Xanthine and Uric Acid in Hypoxic-Ischemic Encephalopathy Neonates. Clin Pharmacokinet. 2021;doi: 10.1007/s40262-021-01068-0.
Chu, W. Y., Annink, K. V., Nijstad, A. L., Maiwald, C. A., Schroth, M., Bakkali, L. E., van Bel, F., Benders, M. J. N. L., van Weissenbruch, M. M., Hagen, A., Franz, A. R., Dorlo, T. P. C., Allegaert, K., Huitema, A. D. R. (2021). Pharmacokinetic/Pharmacodynamic Modelling of Allopurinol, its Active Metabolite Oxypurinol, and Biomarkers Hypoxanthine, Xanthine and Uric Acid in Hypoxic-Ischemic Encephalopathy Neonates. Clinical pharmacokinetics, . https://doi.org/10.1007/s40262-021-01068-0
Chu, Wan-Yu, et al. "Pharmacokinetic/Pharmacodynamic Modelling of Allopurinol, its Active Metabolite Oxypurinol, and Biomarkers Hypoxanthine, Xanthine and Uric Acid in Hypoxic-Ischemic Encephalopathy Neonates." Clinical pharmacokinetics vol. (2021). doi: https://doi.org/10.1007/s40262-021-01068-0
Chu WY, Annink KV, Nijstad AL, Maiwald CA, Schroth M, Bakkali LE, van Bel F, Benders MJNL, van Weissenbruch MM, Hagen A, Franz AR, Dorlo TPC, Allegaert K, Huitema ADR. Pharmacokinetic/Pharmacodynamic Modelling of Allopurinol, its Active Metabolite Oxypurinol, and Biomarkers Hypoxanthine, Xanthine and Uric Acid in Hypoxic-Ischemic Encephalopathy Neonates. Clin Pharmacokinet. 2021 Oct 07; doi: 10.1007/s40262-021-01068-0. Epub 2021 Oct 07. PMID: 34617261.
Copy Download .nbib Format: NLM
Correction to: Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor.

Clinical pharmacokinetics

James AJ, Smith CC, Litzow M, Perl AE, Altman JK, Shepard D, Kadokura T, Souda K, Patton M, Lu Z, Liu C, Moy S, Levis MJ, Bahceci E.
PMID: 34297319
Clin Pharmacokinet. 2021 Sep;60(9):1251. doi: 10.1007/s40262-021-01060-8.

No abstract available.

Cite
James AJ, Smith CC, Litzow M, et al. Correction to: Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor. Clin Pharmacokinet. 2021;60(9):1251doi: 10.1007/s40262-021-01060-8.
James, A. J., Smith, C. C., Litzow, M., Perl, A. E., Altman, J. K., Shepard, D., Kadokura, T., Souda, K., Patton, M., Lu, Z., Liu, C., Moy, S., Levis, M. J., & Bahceci, E. (2021). Correction to: Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor. Clinical pharmacokinetics, 60(9), 1251. https://doi.org/10.1007/s40262-021-01060-8
James, Angela Joubert, et al. "Correction to: Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor." Clinical pharmacokinetics vol. 60,9 (2021): 1251. doi: https://doi.org/10.1007/s40262-021-01060-8
James AJ, Smith CC, Litzow M, Perl AE, Altman JK, Shepard D, Kadokura T, Souda K, Patton M, Lu Z, Liu C, Moy S, Levis MJ, Bahceci E. Correction to: Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor. Clin Pharmacokinet. 2021 Sep;60(9):1251. doi: 10.1007/s40262-021-01060-8. PMID: 34297319; PMCID: PMC8416867.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 106 entries